Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06390059
- Locations
- 🇪🇸
University Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸University Hospital Foundation Jimenez Diaz, Madrid, Spain
🇪🇸Clara Campal Comprehensive Cancer Center (CIOCC), Madrid, Spain
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 436
- Registration Number
- NCT06382142
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT06377566
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Francesco De Cobelli
- Target Recruit Count
- 33
- Registration Number
- NCT06375915
- Locations
- 🇮🇹
Department of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT06370754
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT06370871
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 188
- Registration Number
- NCT06360354
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 81
- Registration Number
- NCT06359275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanhai, China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT06343948
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06331845
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.